


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Substitute for form 1449PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **1** of **3**

### Complete if Known

Application Number	10/080,499
Filing Date	February 22, 2002
First Named Inventor	Levesque et al.
Art Unit	1615
Examiner Name	C.A. AZPURU
Attorney Docket Number	701826/52470

FEB 20 2004

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code <sup>2</sup> (if known)			
[Signature]	AA	US-6,348,312	02-19-2002	Peyman et al.	
	AB	US-6,071,305	06-06-2000	Brown, et al.	
	AC	US-6,066,720	05-23-2000	Seela eta l.	
	AD	US-6,028,182	02-22-2000	Uhlmann et al.	
	AE	US-5,429,634	07-04-1995	Narciso, Jr.	
	AF	US-5,500,013	03-19-1996	Buscemi, et al.	
	AG	US-5,443,458	08-22-1995	Eury	
	AH	US-5,342,348	08-30-1994	Kaplan	
	AI	US-5,649,977	07-22-1997	Campbell	
	AJ	US-5,700,286	12-23-1997	Tartaglia, et al.	
[Signature]	AK	US-5,972,027	10-26-1999	Johnson	
	AL	US-5,234,456	08-10-1993	Silvestrini	
	AM	US-4,888,278	12-19-1989	Singer, Robert H. et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	†
		Country Code <sup>2</sup>	Number	Kind Code <sup>5</sup> (if known)				
[Signature]	BA	EP	490,434	A	06-17-1992	AKZO NV		
	BB	WO	95/19167	A	07-20-1995	Mallinckrodt Medical Inc.		
	BC	WO	93/09813	A	05-27-1993	Imp. Cancer Res. Tech.		
	BD	WO	97/14440	A	04-24-1997	Johnson & Johnson		
[Signature]	BH	EP	599,077	A	06-01-1994	Yeda Res. & Dev.		
	BI	WO	94/00472	A	01-06-1994	Res. Corp. Technologies Inc.		

Examiner Signature

[Signature]

Date Considered

3/01/05

\*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Substitute for form 1449PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	10/080,499
			Filing Date	February 22, 2002 FEB 20 2004
			First Named Inventor	Levesque et al.
			Art Unit	1615
			Examiner Name	C.A. AZPURU
			Attorney Docket Number	701826/52470
Sheet	2	70	3	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	CA	Lauren E. BLACK et al., "Regulatory Considerations for Oligonucleotide Drugs: Updated Recommendations for Pharmacology and Toxicology Studies", <i>Antisense Research and Development</i> , 4:299-301, (1994);	
	CB	Jean Paul R. HERMAN et al., "Pharmacological Approaches to the Prevention of Restenosis Following Angioplasty The Search for the Holy Grail? (Part 1)", <i>Drugs</i> , 46(1):18-52, (1993);	
	CC	Ran KORNOWSKI et al., "In-Stent Restenosis: Contributions of Inflammatory Responses and Arterial Injury to Neointimal Hyperplasia", <i>Experimental Studies</i> , 31(1):224-30, (1998);	
	CD	Robert S. SCHWARTZ et al., "Recommended Standards for PreClinical Studies And Evaluation of Drug Eluting Stents A Consensus Report", Version 1.00	
	CE	WEITIAN TAN et al., <i>Tetrahedron Letters</i> , 36(30): 5323-5326, 1995	
	CF	VILLA et al., <i>Circulation Research</i> , 76(4): 505-513, 1995	
	CG	FARRELL et al., <i>Antisense Research and Development</i> , 5(3): 175-183, 1995	
	CH	DATABASE WPI, Section Ch, Week 9310, Derwent Publications Ltd., London, 1993	
	CI	AZRIN et al., <i>Catheterization and Cardiovascular Diagnosis</i> , 41(3): 232-240, 1997	
	CJ	ROBINSON et al., <i>Catheterization and Cardiovascular Diagnosis</i> , 41(3): 354-359, 1997	

Examiner Signature		Date Considered	3/01/05
--------------------	--	-----------------	---------

\*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Applicant's unique citation designation number (optional); <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/080,499		
		Filing Date	February 22, 2002		
		First Named Inventor	Levesque et al.		
		Art Unit	1615		
		Examiner Name	C.A. AZPURU		
Sheet	3	70	3	Attorney Docket Number	701826/52470



FEB 20 2004

	CK	CHEMLA et al., <i>Arch. Mal. Cœur.</i> , 88(3): 381-389, 1995	
	CL	CHANG et al., <i>Mol. Med.</i> , 1(2): 172-181, 1995	
	CM	TJUVAJEV J.G. et al., <i>Cancer Research</i> , 55(24): 6126-6132, 1995.	

Examiner Signature		Date Considered	03/01/05
--------------------	--	-----------------	----------

\*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.